12 results about "Leucine zipper" patented technology

The application discloses a kind of locust rearing screening devices, it is related to locust rearing device technical field.The supporting frame, first screening unit, second screening unit and excrement collection unit are included;First screening unit includes first frame and first screening frame, one side of first screening frame is rotatably connected with first frame, and the other side is connected with first frame by first buckle, and first screening frame can be turned down;Similarly, second screening frame can also be turned down.First screening frame includes first pull rod, first screen and first telescopic motor, and first telescopic motor is used to control first screen to realize the screening of locust by horizontal reciprocating motion, and similarly, second screening frame can also realize screening.The locust rearing screening device provided in the application has simple structure, can automatically batch screen locusts, and can also automatically load locusts into insect rearing cloth bag after screening.

The invention relates to a method for improving the prokaryotic expression quantity of CRISPR-dCas9 (clustered regularly interspaced short palindromic repeats) protein. Specifically, the invention relates to a method for improving the expression level of dCas9 protein in a prokaryotic cell, and a leucine zipper gene sequence and a dCas9 gene sequence are connected and introduced into the prokaryotic cell. According to the method, the high-purity and high-concentration dCas9 protein can be obtained, the expression quantity of the dCas9 protein is remarkably higher than that of a common method using maltose binding protein (MBP) as a fusion molecular chaperone, the obtained dCas9-lzip fusion protein still has the capability of being normally combined with DNA in a targeted manner under the guidance of sgRNA, and the function of dCas9 is not influenced by connection of a lzip sequence.

The presently disclosed subject matter provides compositions and systems for cell-based immunotherapy. In certain non-limiting embodiments, the system comprises a membrane-bound polypeptide and at least one soluble polypeptide that is capable of dimerizing with the membrane-bound polypeptide.

The present invention relates generally to antibodies and antigen-binding fragments thereof, in particular those targeting cancer- associated antigens, compositions comprising the same, and methods and uses thereof for detecting cancer-associated antigens in tissues, including prostate cancer tissues. Also provided herein are methods for detecting prostate cancer in a subject, methods for detecting and measuring the severity of prostate cancer in a subject, methods for monitoring the progression of prostate cancer in a subject, methods for determining the likelihood of the presence of prostate cancer in a subject, methods for identifying a subject suffering from prostate cancer who is likely to respond to cancer therapy, methods for predicting the risk of recurrence of prostate cancer in a subject following treatment with a cancer therapy, methods for treating prostate cancer in a subject, methods of stratifying a subject for prostate cancer therapy, uses of anti-cancer agent in the manufacture of a medicament for treating prostate cancer in a subject, and an anti-cancer agent for use in the treatment of prostate cancer in a subject, based upon the detection of specific protein biomarkers with the antibodies described herein. Also contemplated are immunoassays, including immunohistochemistry (IHC) and immunofluorescence (IF), to detect specific protein biomarkers in biological samples. The preferred biomarkers include endosomal proteins, such as Adaptor protein, phosphotyrosine interacting with PH domain and leucine zipper 1 (APPL1), sortilin-1 (SORT1), Syndecan-1 (SDC1).

The present invention relates to a conjugate. The conjugate comprises a chimeric immunoglobulin and a conjugation partner, wherein the chimeric immunoglobulin comprises an antigen-binding fragment and a leucine zipper, and the leucine zipper is linked to the terminus of the antigen-binding fragment.

A conjugate is provided. The conjugate includes a chimeric immunoglobulin and a conjugation partner, the chimeric immunoglobulin including an antigen binding fragment and a leucine zipper, the antigen binding fragment being terminally linked to the leucine zipper.

The application discloses a recombinant carrier for preparing HLA / beta 2M complex and a preparation method and application thereof, relates to the technical field of antibody preparation of MHC-polypeptide complex, and provides a recombinant carrier for preparing HLA / beta 2M complex, wherein FOS leucine zipper bZIP motif is inserted between NheI / AvrII enzyme cutting sites of an original carrier, JUN leucine zipper bZIP motif is inserted between BsiWI / BlpI enzyme cutting sites, beta 2M gene sequence is inserted between AgeI / NheI enzyme cutting sites, and HLA sequence is inserted between specific enzyme cutting sites, so that the prepared HLA / beta 2M complex has high expression, and the highest expression reaches 92.45 mg / L.

Non-invasive, in situ forming depots for delivery of a therapeutic agents, containing heterodimerizing, synthetic leucine zippers for physical crosslinking mediated by competition-based dimerization. The heterodimerizing, synthetic leucine zippers form a self-assembling depot of the therapeutic agent at a target site in vivo. A library of such heterodimerizing, synthetic leucine zippers is provided, as well as methods of treating subjects using the same.

The invention discloses application of a soybean GmbZIP104 gene in adaptation of plants to high-salt environmental stress, and belongs to the technical field of plant genetic engineering. The nucleotide sequence of the cDNA of the GmbZIP104 gene is as shown in SEQ ID NO. 1; as shown in SEQ ID NO. 2, the amino acid sequence of the GmbZIP104 is shown in SEQ ID NO. The soybean GmbZIP104 gene disclosed by the invention is used for coding a transcription factor consisting of an alkaline region and a leucine zipper structure. The expression quantity is reduced under the condition of soybean salt stress, and by knocking out the GmbZIP104 gene in a soybean body, the symptom represented by the soybean subjected to the salt stress can be relieved; overexpression of the GmbZIP104 gene (GmbZIP104-OE) can cause the salt stress symptom aggravation of soybeans, and the GmbZIP104 gene is a negative regulation salt stress gene. The gene provides a new target gene for breeding a high-salt soybean variety, and provides a theoretical basis for cultivating a high-quality salt-tolerant soybean variety.

The present invention relates to compositions and methods for modifying homeodomain-leucine zipper (HD-Zip) transcription factors in plants to inhibit shade avoidance responses in plants. The present invention also relates to plants produced using the methods and compositions of the present invention.

The application provides a truncated transposase, a transposon system and application thereof. Compared with a wild-type PS transposase, the truncated transposase lacks 1-50 amino acids at the C terminal of the wild-type PS transposase, preferably 44 amino acids. By deleting the amino acids at the C terminal of the transposase which have less influence on transposition, the length of the transposase is shortened, which is beneficial to the expression of the transposase and the preparation of a fusion protein, so that a transposase or a fusion protein thereof with higher catalytic activity and smaller size is obtained. The application also provides a fusion protein of the transposase, which is preferably fused with a leucine zipper through a linker, and a transposon system comprising the transposase and the transposon, which has great application value in the transgenic industry.

The invention provides a nano antibacterial peptide based on a leucine zipper and a preparation method and application thereof, and belongs to the technical field of biology, and the amino acid sequence of the nano antibacterial peptide is as shown in SEQ ID No.1. The antibacterial peptide disclosed by the invention has self-assembly capability, can be assembled to form a compact nanofiber net, has an antibacterial effect on gram-negative bacteria including escherichia coli, pseudomonas aeruginosa and salmonella typhimurium and gram-positive bacteria including staphylococcus aureus, staphylococcus epidermidis and enterococcus faecalis, and meanwhile, has relatively high biocompatibility, so that the antibacterial peptide can be used for preparing the antibacterial peptide. Moreover, the antibacterial peptide disclosed by the invention can stably exert an antibacterial effect under the conditions of serum, acid and alkali. In conclusion, the antibacterial peptide disclosed by the invention is an antibacterial peptide with relatively good antibacterial activity and biocompatibility.